Obviously. It's a sign that regulators are taking the drug seriously.
OPT at the time of wAMD PhII results was a $200m company. Even though DXB is half of that now, doesn't mean we can't compare them in some ways.
DXB vs OPT pre release, page-4
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.030(8.00%) |
Mkt cap ! $225.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 40.5¢ | 37.0¢ | $637.2K | 1.624M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16500 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 169113 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |